MaxCyte, Inc. (NASDAQ:MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today announced that it has entered into a technology license partnership with Genentech, a member of the Roche Group, to support the development of cell therapy programs.

The license provides Genentech with access to MaxCyte’s ExPERT GTx® platform and additional platform technologies across select research, clinical development, and manufacturing workflows. Structured to support multiple programs, the license enables Genentech to support ex vivo applications for cell engineering.    

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.